Massachusetts House Bill H1330

Massachusetts 2025-2026 Regular Session

• Introduced: 2/27/25
• Refer: 2/27/25

Caption

Relative to pharmacy benefit managers reimbursements to pharmacies in the Commonwealth

Impact

If enacted, H1330 would impose new obligations on PBMs, including providing pharmacies with access to their maximum allowable cost lists and instituting a fair administrative appeals process. The timely updating of these lists—within seven days of significant cost changes or methodology modifications—is designed to ensure that pharmacies are fairly compensated and can continue to serve their customers without financial distress. Additionally, by explicitly defining terms such as 'pharmacy acquisition cost' and establishing conditions under which drugs can be listed, the bill aims to prevent unfair pricing practices by PBMs.

Summary

House Bill H1330, introduced by Representative Alyson M. Sullivan-Almeida, addresses the regulations surrounding pharmacy benefit managers (PBMs) and their reimbursement practices to pharmacies within Massachusetts. The bill aims to create a more transparent and equitable reimbursement framework by stipulating that PBMs must maintain a maximum allowable cost list for drugs and provide timely updates to pharmacies. This legislation responds to concerns that current practices may result in pharmacies being reimbursed at rates lower than the acquisition costs they incur for these drugs, which can jeopardize their operations and service availability in the community.

Contention

Some points of contention surrounding H1330 may arise from the implementation of compliance measures for PBMs and how this would interact with existing state laws and regulations concerning pharmaceutical practices. Critics might argue that further regulation could inadvertently lead to increased operational burdens on PBMs, which they may pass on to consumers in the form of higher drug prices. Proponents, however, emphasize that the bill is necessary to protect pharmacies and improve healthcare access for residents by ensuring better reimbursement practices. The language in the bill that categorizes violations as deceptive business practices could also prompt further debate about enforcement mechanisms within the healthcare market.